Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson by Joshua J. Field, Gene.

Slides:

Advertisements

Similar presentations

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

Advertisements

Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma by Joshua Richter, Natalia Neparidze,

SAP mediates specific cytotoxic T-cell functions in X- linked lymphoproliferative disease by Reza Sharifi, Joanna C. Sinclair, Kimberly C. Gilmour, Peter.

Dosing lepirudin in patients with heparin-induced thrombocytopenia and normal or impaired renal function: a single-center experience with 68 patients by.

Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease by Marilyn J. Telen Blood Volume 127(7): February 18, 2016 ©2016 by.

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene by Xiaoou Zhou,

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation by Xiaoou Zhou, Gianpietro.

Lenalidomide augments actin remodeling and lowers NK- cell activation thresholds by Kathryn Lagrue, Alex Carisey, David J. Morgan, Rajesh Chopra, and Daniel.

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Determination of acute lung injury after repeated platelet transfusions by Laurence Corash, Jin Sying Lin, Claire D. Sherman, and Joseph Eiden Blood Volume.

Gene therapy: efficient targeting of hematopoietic stem cells

Do HSCs divide asymmetrically?

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

TCR-MHC-peptide(s): in vivo veritas

“Vitamin hypothesis”: explanation for allergy increase?

by Khaled M. Musallam, Vijay G

by Timothy P. Hughes, and David M. Ross

The Hyperresponsiveness of Cells Expressing Truncated Erythropoietin Receptors Is Contingent on Insulin-Like Growth Factor-1 in Fetal Calf Serum by Jacqueline.

Finding a diamond in the (mouse is) rough

Positioning NK-κB in multiple myeloma

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Tax fingerprint in adult T-cell leukemia

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia by John C. Byrd, Guido Marcucci,

How I treat elderly patients with myeloma

Elevated Plasma Von Willebrand Factor and Decreased ADAMTS13 Antigen Levels in Patients with Immune Thrombocytopenia (ITP)‏ by Charlotte Louise Godfrey,

Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients by Nicola Giuliani, Francesca Morandi, Sara Tagliaferri, Simona Colla,

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Topical Sodium Nitrite Is Effective In Reducing Leg Ulcer-Associated Pain In Patients With Sickle Cell Disease by Caterina P. Minniti, Caroline Cantilena,

Pregnancy outcomes after maternal exposure to rituximab

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Fusion genes in cord blood

An Unusual Cause of Abdominal Pain in Sickle Cell Disease

Serum Levels of Substance P Are Elevated in Patients With Sickle Cell Disease and Increase Further During Vaso-Occlusive Crisis by Lisa A. Michaels, Kwaku.

Engineering regulatory T cells against factor VIII inhibitors

Mutation Analysis of the Rearranged Immunoglobulin Heavy Chain Genes of Marginal Zone Cell Lymphomas Indicates an Origin From Different Marginal Zone B.

Relationship of p53, bcl-2, and Tumor Proliferation to Clinical Drug Resistance in Non-Hodgkin's Lymphomas by Wyndham H. Wilson, Julie Teruya-Feldstein,

by Lewis Hsu, Bhalchandra Diwan, Jerrold M. Ward, and Constance T

Taking a leaf from the book of oral tolerance

T cell receptor Vβ (TCR-Vβ) expression in a drug-specific T cell line (TCL) and specificity assay of a TCL of patient P1. T cell receptor Vβ (TCR-Vβ) expression.

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

by Robert McMillan, Jennifer Lopez-Dee, and Joseph C. Loftus

Stage C or not stage C…? by Claire Dearden Blood

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

by Jon E. Arnason, Federico Campigotto, Donna Neuberg, and James B

Lymphoma spread? Target CD47-SIRPα!

Anergy: the CLL cell limbo

by John J. Strouse, Megan E. Reller, David G

Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal.

by Martin S. Tallman, Donna Neuberg, John M. Bennett, Christopher J

by Santosh L. Saraf, Xu Zhang, Tamir Kanias, James P. Lash, Robert E

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Overcoming “aspirin resistance” in MPN

Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy by Wyndham H. Wilson, Michael L. Grossbard,

Erratum in Ledru et al. Alteration of tumor necrosis factor–α T-cell homeostasis following potent antiretroviral therapy: contribution to the development.

by Hao Xu, Nancy J. Wandersee, YiHe Guo, Deron W. Jones, Sandra L

Sickle cells and sickle trait in thrombosis

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers by Paul J Neeson, Alexander James Davenport, Joseph A Trapani, Michael.

Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease by Joshua J. Field, Elaine Majerus, Victor.

Biology and treatment of Richter syndrome

Rituximab immunotherapy: it’s getting personal

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Pure red cell aplasia by Robert T. Means Blood

by Andy Hsu, Hang Quach, Tsin Tai, H. Miles Prince, Simon J

Patient Tregs express normal levels of suppression.

by Chatree Chai-Adisaksopha, Davide Matino, and Alfonso Iorio

Chimeric antigen receptor–modified T cells: CD19 and the road beyond

Is Skull-Base to Proximal Thigh PET/CT Enough

Cold agglutinin disease

Presentation transcript:

Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A 2A receptor agonist regadenoson by Joshua J. Field, Gene Lin, Maureen M. Okam, Elaine Majerus, Jeffrey Keefer, Onyinye Onyekwere, Ainsley Ross, Federico Campigotto, Donna Neuberg, Joel Linden, and David G. Nathan Blood Volume 121(17): April 25, 2013 ©2013 by American Society of Hematology

Phospho-NF-κB p65, A2AR, and IFN-γ expression in iNKT cells of controls and patients in steady state and pVOC (stages 2 and 3, respectively) at time 0 (preinfusion). Joshua J. Field et al. Blood 2013;121: ©2013 by American Society of Hematology

Phospho-NF-κB p65 expression in iNKT cells in subjects who received a 1.44 μg/kg/h regadenoson infusion for 24 hours with a 6-hour observation period when no drug was infused. Joshua J. Field et al. Blood 2013;121: ©2013 by American Society of Hematology

Pharmacokinetics of regadenoson infused for 12 hours during stage 1. Joshua J. Field et al. Blood 2013;121: ©2013 by American Society of Hematology